Given the currently available preclinical evidence, we postulate that cancer cell metabolic plasticity and redundancies in metabolic regulatory mechanisms mean that it is unlikely that targeting HIF-1 on its own will be sufficient to disrupt the metabolism of cancer cells and produce meaningful clinical benefit. Here, HIF1A is linked to cancer.